核心技术

Core Technology

STLenti®

STLenti® is an advanced lentiviral (LV) platform designed to provide an efficient gene delivery system tailored to clinical needs. By incorporating cutting-edge technologies, we enhance the precision of targeting and the safety of LVs, enabling advanced applications in precision gene therapy.

Platform Features:

  1. Advanced Programmability: STLenti® offers versatile programming capabilities, enabling the customization of vector characteristics to meet specific requirements. This allows for precise targeting and delivery to desired tissues.

  2. Enhanced Targeting: Leveraging advanced vector design technologies, STLenti® optimizes targeting accuracy, ensuring the precise delivery of gene therapy treatments to target tissues, thereby improving therapeutic outcomes.

  3. Safety Assurance: STLenti® has undergone extensive optimization to minimize in vivo side effects. A rigorous testing and validation process ensures the vector's safety and efficacy in clinical applications.

  4. Efficient Production: The platform employs high cell-density suspension culture technology and serum-free media, combined with high-throughput single-cell microfluidic screening, ensuring both production efficiency and consistency.

Applications:

  1. Transient Therapeutic Gene Delivery: Efficiently delivers therapeutic genes to the body, supporting transient therapies in clinical applications.

  2. mRNA Vaccine Delivery: Offers a reliable platform for the development and delivery of mRNA vaccines, enhancing immunogenic response.

  3. Gene Editing Tool Delivery: Facilitates the efficient delivery of gene editing tools, such as CRISPR, advancing the therapeutic use of gene editing technologies.


第五代慢病毒载体平台

STLenti® delivers an efficient gene delivery solution while also providing strong support to research teams in both drug development and clinical applications. With this platform, we are dedicated to advancing the real-world application of gene therapy technologies, addressing the increasing need for precision medicine in modern healthcare.

PDX动物模型平台

STPDX®

STPDX® utilizes directed differentiation and gene editing to provide stable 2D primary cell models, 3D organoid models, patient-derived tumor xenograft (PDX) models, gene-edited mouse models, and drug-induced models. These tools are vital for validating therapeutic strategies in our research pipeline and enhancing data accumulation in new drug development.

Platform Features:

  1. Comprehensive Model System: STPDX® includes a range of models, such as 2D primary cells, 3D organoids, patient-derived tumor xenograft (PDX) models, gene-edited mice, and drug-induced models, supporting research needs at various stages.

  2. Efficacy and Pathological Evaluation: We offer independent efficacy evaluation and toxicology testing services to comprehensively assess the safety and effectiveness of gene therapy drugs, ensuring the reliability of research outcomes.

Application Advantages:

  1. Rapid Validation: We quickly and stably create and optimize various models, accelerating the validation and optimization processes in drug development.

  2. Precise Assessment: STPDX® provides accurate evaluations of the safety and efficacy of gene therapy drugs, facilitating in-depth progress in preclinical research.

STProd®

Santo is set to launch the STProd® stable cell line serum-free suspension process system, an advanced LV production platform based on stable cell lines. This system integrates a high-throughput single-cell microfluidic platform, automating the selection and testing of optimal clones, along with high cell-density suspension culture technology, using our specially developed serum-free media for production.

Platform Features:

  1. High-Throughput Screening: STProd® automates the selection and evaluation of optimal clones, ensuring efficiency and stability throughout the production process.

  2. Serum-Free Culture: By utilizing specialized serum-free media for high cell-density suspension culture, the system effectively enhances production efficiency while reducing costs.

  3. Production Optimization: This platform significantly lowers the production costs of LVs while improving production capacity and product quality, delivering efficient and reliable vector support for gene therapy and other applications.

The Santo LV stable cell line, serum-free suspension system from Genscript represents our latest advancements in vector production technology. It will further promote innovative development in the field of gene therapy.

神拓慢病毒生产优化平台
PDX动物模型平台

Cyto-Mine®

Santo is applying the globally leading Cyto-Mine® instrument to develop a new generation of virus production processes. This platform is designed and developed by Santo's partner, Sphere Fluidics, based in the UK, and it empowers cell line engineering, efficient sorting, drug development, and activity detection in the biotechnology field, bringing an innovative revolution to the biopharmaceutical industry.

Instrument Features:

  1. Efficient Screening: Screening of millions to tens of millions of cells can be completed in one day.

  2. Integrated Culturing: Produces microdroplets of 450 pL that encapsulate single cells and reagents, with the capability for incubation at 37 degrees Celsius.

  3. Fluorescence Detection: Equipped with fluorescence signal pathways, enabling the sorting of positive cells using fluorescence signals.

  4. Multi-level Sorting: Two-level sorting can be performed to further isolate positive cells.

  5. Monoclonal Origin Verification: High-performance imaging is used to verify the origin of single cells.

Application Advantages:

  1. Shortened Development Cycles: Greatly reduces development cycles, such as the discovery of monoclonal antibodies (reduced by 2 months), the development of stable CHO cell lines (reduced by 3 months), the development of stable cell lines for virus production (reduced by 6 months), and the engineering of iPSC cells (reduced by 3 months).

  2. Improved Cell Viability: The T cell sorting and MSC cell sorting provided by this instrument offer higher cell viability compared to traditional processes.

  3. Efficient Online Transfection: The online transfection technology provided by this instrument allows for the engineering of cell lines to be completed on the device, using less DNA and PEI reagents while achieving the same or even higher transfection efficiency.